Acyldepsipeptide Antibiotics and a Bioactive Fragment Thereof Differentially Perturb Mycobacterium tuberculosis ClpXP1P2 Activity in Vitro

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Proteolytic complexes in Mycobacterium tuberculosis (Mtb) are crucial drug targets.
• Clp proteases, essential for Mtb viability, involve ClpP1P2 peptidase and ATP-dependent chaperones (ClpX, ClpC1).
• Acyldepsipeptide antibiotics (ADEPs) inhibit Clp protease activity by blocking interactions between ClpP1P2 and chaperones.

Purpose of the Study:

• To investigate a novel fragment of ADEPs for anti-Mtb activity.
• To elucidate the mechanism of action of the ADEPs fragment on Clp protease activity.
• To define the pharmacophore of the bioactive fragment for new drug lead development.

Main Methods:

• Biochemical assays to assess Clp protease activity.
• Structure-activity relationship studies of ADEPs fragments.
• Analysis of ClpXP1P2 complex stabilization.

Main Results:

• A fragment of ADEPs exhibits anti-Mtb activity.
• The fragment stimulates, rather than inhibits, ClpXP1P2-catalyzed protein degradation.
• The fragment stabilizes the ClpXP1P2 complex and binds distinctively from intact ADEPs.

Conclusions:

• The ADEPs fragment represents a new class of Clp protease modulators.
• This discovery opens new therapeutic strategies for tuberculosis treatment.
• The defined pharmacophore will guide the development of novel anti-tuberculosis drug leads.